STOCK TITAN

Kiniksa Pharmaceuticals to Present at 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced its participation in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference. The event will take place on Tuesday, September 28, 2021, at 10:40 a.m. Eastern Time. Interested parties can access the live webcast via the Investors & Media section of Kiniksa's website, with a replay available approximately 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for serious diseases, with its portfolio including ARCALYST®, mavrilimumab, vixarelimab, and KPL-404, targeting significant unmet medical needs.

Positive
  • None.
Negative
  • None.

HAMILTON, Bermuda, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 10:40 a.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio of assets, ARCALYST® (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts!™

Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com


FAQ

What is the date and time of Kiniksa's presentation at the Cantor Fitzgerald Conference?

Kiniksa's presentation will take place on September 28, 2021, at 10:40 a.m. Eastern Time.

Where can I watch Kiniksa's presentation from the conference?

The live webcast of Kiniksa's presentation will be available on their website in the Investors & Media section.

Will there be a replay of Kiniksa's presentation?

Yes, a replay of the webcast will be available on Kiniksa's website approximately 48 hours after the event.

What are some products in Kiniksa's portfolio?

Kiniksa's portfolio includes ARCALYST®, mavrilimumab, vixarelimab, and KPL-404, which target serious diseases with unmet medical needs.

What is Kiniksa Pharmaceuticals focused on?

Kiniksa Pharmaceuticals is focused on discovering and developing therapeutic medicines for patients with debilitating diseases.

Kiniksa Pharmaceuticals International, plc

NASDAQ:KNSA

KNSA Rankings

KNSA Latest News

KNSA Stock Data

1.51B
39.78M
4.15%
98%
5.84%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
LONDON